Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

17.14 +0.65 (+3.94%)
Streaming Delayed Price Updated: 1:44 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 916,939
Open 16.77
Bid (Size) 17.12 (4)
Ask (Size) 17.14 (4)
Prev. Close 16.49
Today's Range 16.58 - 17.39
52wk Range 6.360 - 35.68
Shares Outstanding 58,310,703
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics Appoints Brian Posner to its Board of Directors
From Dyne Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-32.7%
-32.7%
1 Month
+29.9%
+29.9%
3 Month
+85.5%
+85.5%
6 Month
+54.3%
+54.3%
1 Year
-47.0%
-47.0%

More News

Read More
Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics to Present at Upcoming Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates ClaimsOn Behalf of Investors of Dyne Therapeutics, Inc. - DYN
From Pomerantz LLP
Via GlobeNewswire
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
From Pomerantz LLP
Via GlobeNewswire
These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss
Via Benzinga
Dyne Reports Wider Loss in Fiscal Q2
Via The Motley Fool
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
From Pomerantz LLP
Via GlobeNewswire
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
From Dyne Therapeutics, Inc.
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
From Pomerantz LLP
Via GlobeNewswire
Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Why Thumzup Media Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock
From Dyne Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga

Frequently Asked Questions

Is Dyne Therapeutics, Inc. - Common Stock publicly traded?
Yes, Dyne Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Dyne Therapeutics, Inc. - Common Stock trade on?
Dyne Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Dyne Therapeutics, Inc. - Common Stock?
The ticker symbol for Dyne Therapeutics, Inc. - Common Stock is DYN on the Nasdaq Stock Market
What is the current price of Dyne Therapeutics, Inc. - Common Stock?
The current price of Dyne Therapeutics, Inc. - Common Stock is 17.14
When was Dyne Therapeutics, Inc. - Common Stock last traded?
The last trade of Dyne Therapeutics, Inc. - Common Stock was at 10/24/25 01:44 PM ET
What is the market capitalization of Dyne Therapeutics, Inc. - Common Stock?
The market capitalization of Dyne Therapeutics, Inc. - Common Stock is 999.45M
How many shares of Dyne Therapeutics, Inc. - Common Stock are outstanding?
Dyne Therapeutics, Inc. - Common Stock has 999M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.